While RAPT Therapeutics Inc has underperformed by -1.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RAPT fell by -59.38%, with highs and lows ranging from $27.35 to $6.86, whereas the simple moving average fell by -53.74% in the last 200 days.
On February 22, 2024, UBS Downgraded RAPT Therapeutics Inc (NASDAQ: RAPT) to Neutral. A report published by Leerink Partners on February 21, 2024, Downgraded its rating to ‘Market Perform’ for RAPT. JP Morgan also Downgraded RAPT shares as ‘Neutral’, setting a target price of $15 on the company’s shares in a report dated February 21, 2024. Cantor Fitzgerald February 20, 2024d its ‘Overweight’ rating to ‘Neutral’ for RAPT, as published in its report on February 20, 2024. Wolfe Research also rated the stock as ‘Outperform’.
Analysis of RAPT Therapeutics Inc (RAPT)
In order to gain a clear picture of RAPT Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -59.56% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.41, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.35M can be a very valuable indicator of volatility for RAPT stock. On a monthly basis, the volatility of the stock is set at 5.66%, whereas on a weekly basis, it is put at 4.32%, with a loss of -1.64% over the past seven days. Furthermore, long-term investors anticipate a median target price of $22.00, showing growth from the present price of $7.80, which can serve as yet another indication of whether RAPT is worth investing in or should be passed over.
How Do You Analyze RAPT Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.96%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 90.51% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RAPT shares are owned by institutional investors to the tune of 90.51% at present.
